je.st
news
Tag: biologics
Genedata Biologics for Biopharma R&D at 10th Annual PEGS
2014-05-05 06:00:00| Industrial Newsroom - All News for Today
Presentations and posters will focus on methodologies for streamlining next-generation antibody discovery and development processes <br /> <br /> Boston, Mass. - Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the Genedata Biologics™ workflow management system will be among the featured presentations and poster sessions at the 10th Annual PEGS Protein Engineering Summit 2014. The Genedata Biologics ...This story is related to the following:Data Communications Software |
Tags: annual
10th
pegs
biologics
Genedata Biologics 4.0 Enables Large-Scale Design, Synthesis, And Testing Of Bispecific Antibodies
2014-04-02 06:26:51| drugdiscoveryonline News Articles
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Biologics™ 4.0, the latest version of its enterprise workflow support and data management solution for biologics R&D
Tags: design
testing
enables
synthesis
AB Sciex Delivers Breakthrough For Therapeutic Biologics With Innovative CESI-MS
2014-03-05 04:34:30| drugdiscoveryonline Home Page
Developing new life-saving drugs and improving the efficacy and quality of existing therapeutic biologics drive the demand for innovation in the biopharmaceutical industry. To address this need, AB Sciex LLC, a global leader in analytical technologies, recently introduced a breakthrough technology solution called CESI-MS
Tags: innovative
delivers
therapeutic
breakthrough
FDA Accepts for Review Mercks Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine
2014-02-20 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biologics License Application for V503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the U.S. Food and Drug Administration. About Merck Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Imraan Munshi, 215-652-0059orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: review
application
human
license
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
2014-01-13 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Expects to Complete Application in First Half of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has started a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application for MK-3475, the companys investigational anti-PD-1 immunotherapy, for patients with advanced melanoma who have been previously treated with ipilimumab. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
application
license
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »